Please login to the form below

Not currently logged in
Email:
Password:

Merck completes €15m Spanish biotech facility expansion

Enlarged Tres Cantos site will help meet demand for fertility and growth hormone drugs
Merck

Merck has completed a €15m investment project at its biotech facility in Spain that will allow it to up production of its fertility and growth hormone disorder treatments by 50%.

The German company said it would also be increasing the number of staff it employs at the facility by 20% thanks to the two-year programme.

The Tres Cantos plant is Merck's main site for the production of active substances in its fertility treatment Gonal-f and endocrine and metabolic disorders treatment Saizen, for which global demand is rising steadily.

Simon Sturge, chief operating officer of Merck's biopharma business, said: “The demand for our core portfolio of medicines keeps increasing worldwide.

“The expansion in Tres Cantos is part of our continuous commitment to deliver high quality medicines at the right time to our patients.”

Merck was able to raise its sales forecast for 2016 earlier this year after a particularly strong second quarter performance, spearheaded by a 23% growth of Gonal-f that saw its sales reach €209m.

The Darmstadt, Germany-headquartered firm has invested around €250m in its healthcare manufacturing network so far this year, including in a new regional hub in Côte d'Ivoire launched just this week.

The hub will serve Merck's operations in French-speaking countries in Central and West Africa, and will oversee two minilabs donated by the company to aid in the region's fight against counterfeit medicines.

Thierry Hulot, head of Merck's biopharma global manufacturing and supply, commented: “We are continuously investing in our manufacturing network to maintain state-of-the-art industry level and adapt its capacity to patient needs for our medicines.

“We are very pleased to have completed the expansion of our Tres Cantos biotech manufacturing facility which plays a leading role in our manufacturing network and exemplifies our culture of safety at work, quality and service.”

Article by
Rebecca Clifford

18th October 2016

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics